Amylin Pharmaceuticals Disappoints Analysts, But Not Investors - Seeking Alpha: "Scott Rothbort submits: When it appeared that yesterday’s results for Amylin Pharmaceuticals Inc. (AMLN) would be met with disappointment, I expected to hunker down for another round of selling.
Instead, AMLN was higher from the opening bell and was one of the few strong stocks in a dismal tape. While sales of its blockbuster Byetta treatment missed analysts’ expectations by a small margin, AMLN other diabetes treatment Symlin appears to be growing faster than anticipated. AMLN has a long acting formulation, Byetta LAR and an obesity treatment, pramlintide, in the pipeline which should provide some excellent future revenue streams if approved. I anticipate LAR to be available in 2009."